Akero Therapeutics, Inc.
https://akerotx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Akero Therapeutics, Inc.
Akero Shows More Strong Fibrosis Data, But Analysts Cite Safety Worry
Akero is developing weekly injectable efruxifermin for MASH with solid 96-week efficacy data and three Phase III studies underway. But will it find a treatment niche in a competitive space?
EASL: Sagimet Pill Is Overlooked But Could Make A Splash In MASH
While injectables have had all the limelight, some analysts see a bright future for Sagimet’s oral denifanstat, potentially as a backbone therapy in combination with other treatments for MASH.
Boehringer Backs Up Best-In-Class MASH Claims With Fibrosis Data
Survodutide burnishes its best-in-class MASH case with a 64% improvement in moderate-to advanced fibrosis at Phase II, but tolerability an issue
EASL: Tirzepatide Is The One To Beat In MASH
An important mid-stage trial succeeds, but an odd finding on the fibrosis endpoint will spur close examination of Lilly’s incretin.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice